U.S. FDA Approves New Indication for the Use of XTANDI(R) (Enzalutamide) Capsules for Patients With Metastatic Castration-Resistant Prostate Cancer
Takeda and Orexigen Announce FDA Approval of Contrave® (naltrexone HCI and bupropion HCI) Extended-release Tablets for Chronic Weight Management
At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme's Lemtrada in Pivotal Studies
Amgen Announces 23 Abstracts To Be Presented At The American Society for Bone and Mineral Research 2014 Annual Meeting
Data Include Eight Year Analyses of Bone Mineral Density Results for Prolia® (Denosumab) and Further Evidence for Significant Bone-Building With Romosozumab
European Commission grants Lilly and Boehringer Ingelheim's insulin glargine product marketing authorisation in Europe
First biosimilar insulin to receive regulatory approval in the EU
INDIANAPOLIS and RIDGEFIELD, Conn.,
Gilenya® data confirm reducing brain shrinkage matters for people with MS due to its association with long-term disability progression
FDA Advisory Committee Recommends Against Approval of Actavis' Nebivolol/Valsartan Fixed-Dose Combination NDA for Treatment of Hypertension
Drug Launch, Market Activity, Appointments, and Special Meeting of Shareholders - Research Reports on Teva, Universal Health, Tenet, Allergan and Valeant
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, September 9, 2014<
SHM-XEL Platform Successfully Generates Novel Therapeutic Approach to Autoimmune Disease
SAN DIEGO, Sept.
-Innovative Abbott testing technology may help to identify severe infections sooner